• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.

作者信息

Re Daniel, Barrière Jérôme, Chamorey Emmanuel, Delforge Margaux, Gastaud Lauris, Petit Emmanuel, Chaminade Axel, Verrière Benjamin, Peyrade Frédéric

机构信息

Department of Medical Oncology, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France.

Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.

出版信息

Leuk Lymphoma. 2021 Dec;62(13):3308-3310. doi: 10.1080/10428194.2021.1957877. Epub 2021 Jul 26.

DOI:10.1080/10428194.2021.1957877
PMID:34308748
Abstract
摘要

相似文献

1
Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.血液系统恶性肿瘤患者接种mRNA抗SARS-CoV-2疫苗后血清转化率低。
Leuk Lymphoma. 2021 Dec;62(13):3308-3310. doi: 10.1080/10428194.2021.1957877. Epub 2021 Jul 26.
2
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.血液恶性肿瘤患者治疗对 SARS-CoV-2 疫苗接种后血清转化率的影响。
Oncologist. 2022 Apr 5;27(4):e357-e361. doi: 10.1093/oncolo/oyac032.
3
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.SARS-CoV-2疫苗接种后，血液系统恶性肿瘤的黑人和西班牙裔人群血清转化率较高。
Leuk Lymphoma. 2022 Oct;63(10):2484-2488. doi: 10.1080/10428194.2022.2074988. Epub 2022 May 20.
4
Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection.预测感染新型冠状病毒肺炎（COVID-19）的免疫功能低下儿童和青少年感染严重程度及血清转化的因素。
Front Immunol. 2022 Aug 3;13:919762. doi: 10.3389/fimmu.2022.919762. eCollection 2022.
5
Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination.血液系统恶性肿瘤患者的治疗、血清转化率和 SARS-CoV-2 疫苗接种。
Oncologist. 2022 Nov 3;27(11):e916. doi: 10.1093/oncolo/oyac169.
6
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.血液系统恶性肿瘤成人接种新型冠状病毒疫苗后的抗体反应：一项系统评价和荟萃分析。
Haematologica. 2023 Feb 1;108(2):653-654. doi: 10.3324/haematol.2022.281902.
7
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
8
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients.抗SARS-CoV-2疫苗在血液系统恶性肿瘤患者中的免疫原性和临床疗效：365例患者的前瞻性队列研究结果
Am J Hematol. 2022 Aug;97(8):E321-E324. doi: 10.1002/ajh.26629. Epub 2022 Jun 24.
9
Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine.实体瘤患者在接种 SARS-CoV-2 mRNA 疫苗后血清转化。
Cancer Discov. 2021 Sep;11(9):2122. doi: 10.1158/2159-8290.CD-RW2021-099. Epub 2021 Jul 16.
10
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination.替沙格韦单抗-西加韦单抗对血液系统恶性肿瘤患者及接种SARS-CoV-2疫苗后无抗体反应患者的预防效果降低。
Eur J Haematol. 2023 Oct;111(4):668-670. doi: 10.1111/ejh.14045. Epub 2023 Jul 18.

引用本文的文献

1
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.免疫预测因子在淋巴瘤和慢性淋巴细胞白血病患者中的疫苗反应。
J Infect Dis. 2024 Jul 25;230(1):15-27. doi: 10.1093/infdis/jiae106.
2
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
3
Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era.
奥密克戎变异株流行期中国真实世界研究：登记注册临床试验中淋巴瘤患者感染 COVID-19 的结局。
Cancer Med. 2023 Dec;12(23):21148-21158. doi: 10.1002/cam4.6678. Epub 2023 Nov 27.
4
COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma.在使用CD20抗体治疗B细胞淋巴瘤的化疗中，通过接种疫苗产生新冠病毒抗体。
Mol Clin Oncol. 2023 Oct 18;19(6):96. doi: 10.3892/mco.2023.2692. eCollection 2023 Dec.
5
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients.完全接种疫苗的血液系统疾病患者对 SARS-CoV-2 病毒及其奥密克戎 BA.1 变异株的有效中和抗体反应。
Clin Exp Med. 2023 Dec;23(8):4943-4953. doi: 10.1007/s10238-023-01223-w. Epub 2023 Oct 28.
6
Prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report.在使用奥妥珠单抗和苯达莫司汀治疗滤泡性淋巴瘤期间出现的新型冠状病毒2型（SARS-CoV-2）长期感染：一例报告
Clin Case Rep. 2023 Aug 28;11(9):e7861. doi: 10.1002/ccr3.7861. eCollection 2023 Sep.
7
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
8
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
9
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后出现持续性 SARS-CoV-2 感染和多次临床复发。
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
10
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.接种疫苗和单克隆抗体后血液系统恶性肿瘤 COVID-19 患者的结局：HM-COV 2.0 研究结果。
Clin Exp Med. 2023 Oct;23(6):2275-2285. doi: 10.1007/s10238-023-01027-y. Epub 2023 Mar 3.